Abstract
Background:
Osteogenesis imperfecta (OI) is characterized by bone fragility and short stature. Data about IGF-I/IGFBP-3 levels are rare in OI. Therefore IGF-I/IGFBP-3 levels in children with different types of OI were investigated.
Methods:
IGF-I and IGFBP-3 levels of 60 children (male n=38) were assessed in a retrospective cross-sectional setting.
Results:
Height/weight was significant different [height z-score type 3 versus type 4: p=0.0011 and weight (p≤0.0001)] between OI type 3 and 4. Mean IGF-I levels were in the lower normal range (mean±SD level 137.4±109.1 μg/L). Mean IGFBP-3 measurements were in the normal range (mean±SD 3.105±1.175 mg/L). No significant differences between OI type 3 and 4 children have been observed (IGF-I: p=0.0906; IGFBP-3: p=0.2042).
Conclusions:
Patients with different severities of OI have IGF-I and IGFBP-3 levels in the lower normal range. The type of OI does not significantly influence these growth factors.
MeSH terms
-
Adolescent
-
Bone Density Conservation Agents / administration & dosage
-
Bone Density Conservation Agents / therapeutic use
-
Child
-
Child, Preschool
-
Cohort Studies
-
Cross-Sectional Studies
-
Diphosphonates / administration & dosage
-
Diphosphonates / therapeutic use
-
Female
-
Growth Disorders / etiology*
-
Hospitals, Pediatric
-
Hospitals, University
-
Humans
-
Infant
-
Infusions, Intravenous
-
Insulin-Like Growth Factor Binding Protein 3 / blood*
-
Insulin-Like Growth Factor I / analysis*
-
Male
-
Osteogenesis Imperfecta / blood
-
Osteogenesis Imperfecta / drug therapy
-
Osteogenesis Imperfecta / physiopathology*
-
Outpatient Clinics, Hospital
-
Retrospective Studies
-
Severity of Illness Index
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
IGF1 protein, human
-
IGFBP3 protein, human
-
Insulin-Like Growth Factor Binding Protein 3
-
Osteogenesis Imperfecta, Type IV
-
Insulin-Like Growth Factor I
-
6-amino-1-hydroxyhexane-1,1-diphosphonate
Supplementary concepts
-
Osteogenesis imperfecta, type 3